Xvivo Perfusion ABXVIPF -1.32%91 Net Current Asset Value is $1.45 as of Mar. 2026, which is 93% below its 10-year median of 20.32. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 567 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 86.24% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Xvivo Perfusion AB's net current asset value per share for the quarter that ended in Mar. 2026 was $1.45.
The historical rank and industry rank for Xvivo Perfusion AB's Net Current Asset Value or its related term are showing as below:
XVIPF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 9.87 Med: 20.32 Max: 62.07
Current: 18.71
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Xvivo Perfusion AB was 62.07. The lowest was 9.87. And the median was 20.32.
XVIPF's Price-to-Net-Current-Asset-Value is ranked worse than 86.24% of 567
companies
in the Medical Devices & Instruments industry
Industry Median: 4.98
vs XVIPF: 18.71
Xvivo Perfusion AB (OTCPK:XVIPF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Xvivo Perfusion AB Net Current Asset Value Related Terms
Xvivo Perfusion AB Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XVIPF vs ABT, SYK, MDT: Net Current Asset Value Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $1.45 mean?
Xvivo Perfusion AB (XVIPF) has a Net Current Asset Value of $1.45 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Xvivo Perfusion AB and its competitors. This is 93% below median its historical median of 20.32. Over the past decade, Xvivo Perfusion AB's Net Current Asset Value has ranged from 9.87 to 62.07. According to the industry distribution chart, Xvivo Perfusion AB ranks #489 out of 567 companies in the Medical Devices & Instruments industry, placing it in the top 86.2%.
Is Xvivo Perfusion AB's Net Current Asset Value too high?
Xvivo Perfusion AB's current Net Current Asset Value of $1.45 is 93% below median its 10-year median of 20.32. Over the past 10 years, this metric has ranged from a low of 9.87 to a high of 62.07. The Medical Devices & Instruments industry median Net Current Asset Value is 4.98. Xvivo Perfusion AB's value of $1.45 is 70.9% below this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #489 out of 567 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Net Current Asset Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #489 out of 567 companies for Net Current Asset Value. This places Xvivo Perfusion AB in the lower half of its industry. The industry median Net Current Asset Value is 4.98. Xvivo Perfusion AB's value of $1.45 is 70.9% below this benchmark. Historically, Xvivo Perfusion AB's own Net Current Asset Value has ranged from 9.87 to 62.07 over the past decade. While the company's 10-year median is 20.32 vs. the industry median of 4.98, Xvivo Perfusion AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.98, based on 567 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Net Current Asset Value of $1.45 is 70.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Net Current Asset Value is $1.45, which is 93% below median its own 10-year median of 20.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current Net Current Asset Value is $1.45, which is 93% below median its 10-year median of 20.32 and 70.9% below the Medical Devices & Instruments industry median of 4.98. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Net Current Asset Value is $1.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Net Current Asset Value: $1.45 (93% below median its 10-year median of 20.32)
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 70.9% below the Medical Devices & Instruments median (#489 of 567)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
